Brentford, United Kingdom - March 18, 2016, Brentford, United Kingdom - GlaxoSmithKline (GSK) announced that Sir Andrew Witty, chief executive officer, will retire on March 31, 2017.
Article continues below
Sir Andrew became Chief Executive Officer of GlaxoSmithKline plc on May 21, 2008. He is a member of the Board and Corporate Executive Team.
Sir Andrew joined Glaxo in 1985 and has held a variety of Sales and Marketing roles in the UK and abroad including working in the Company’s International New Products groups, both in the Respiratory and HIV/Infectious disease fields.
Outside of the UK Sir Andrew has worked in South Africa, the USA and Singapore where he led the Group’s operations as Senior Vice President, Asia Pacific.
While in Singapore Sir Andrew was a Board Member of the Singapore Economic Development Board and the Singapore Land Authority. In 2003 he was awarded the Public Service Medal by the Government of Singapore and in August 2012 was also awarded the Public Service Star.
In 2003 Sir Andrew was appointed President of GSK Europe and joined GSK’s Corporate Executive Team.
Sir Andrew has served in numerous advisory roles to Governments around the world including South Africa, Singapore, Guangzhou China and the UK, where he was a member of the Prime Minister’s Business Advisory Group from 2010 - 2015. He was awarded a Knighthood for services to the economy and to the UK pharmaceutical industry in the 2012 New Year Honours List.
In 2014, Sir Andrew was appointed to be a Business Ambassador for the UK Government and in 2015, he became a member of the China-Britain Business Council Advisory Council. He is Chancellor of the University of Nottingham, a position he took up on 1 January 2013.
Sir Andrew has a Joint Honours BA in Economics from the University of Nottingham.
GSK announced that Sir Deryck Maughan, Stephanie Burns, Daniel Podolsky and Hans Wijers will not stand for re-election to the Board at GSK's Annual General Meeting on May 5, 2016.
Sir Deryck is a Non-Executive Director of BlackRock, Inc. as well as a Trustee of the British Museum and of New York University Langone Medical Center.
Sir Deryck was previously a Senior Advisor and Partner of Kohlberg Kravis Roberts & Co, a Non-Executive Director of Thomson Reuters and served on the Board of Directors of the Lincoln Center.
Sir Deryck was formerly Chairman and Chief Executive Officer of Citigroup International and of Salomon Brothers Inc. He served as Vice Chairman of the New York Stock Exchange from 1996 to 2000.
Dr. Burns was formerly Chairman, President and Chief Executive Officer of Dow Corning Corporation, until her retirement on 31 December 2011. Dr. Burns was appointed a Non-Executive Director of Corning Inc. on 31 January 2012.
Dr. Burns joined Dow Corning in 1983 as a researcher working on water based and high temperature elastomers. She became director of Women's Health in 1994 and subsequently moved into corporate management becoming Science and Technology Director for Europe in 1997.
Dr. Burns was first elected to Dow Corning's Board of Directors in December 2000, she was President and Chief Executive Officer from February 2003 until 2011, Chief Operating Officer from January 2004 until 2011 and was Chairman from January 2006 to December 2011. She has been a member of the Board of HP Inc. since November 2015.
Dr. Burns holds a Ph.D. in organic chemistry, with an organosilicon specialty, from Iowa State University. She completed her post-doctoral studies at the Universite Montpellier, Sciences et Techniques du Languedoc, France.
Dr. Burns is a former Chairman of the American Chemistry Council and has also served on the boards of the Michigan Molecular Institute and the Society for Women’s Health Research.
Mr. Podolsky is President of the University of Texas Southwestern Medical Center in Dallas and holds the Philip O’Bryan Montgomery, Jr M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science.
Mr. Podolsky is a member of the National Academy of Medicine at the US National Academy of Sciences, the Council of Teaching Hospitals of the Association of Academic Medical Centers, and sits on the Board of the Southwestern Medical Foundation.
Mr. Podolsky is also a Director of Antibe Therapeutics, Inc., Agilent Technologies, Inc. and a member of the National Academies of Sciences Board on Army Science and Technology.
Previously, he served as Co-Chairman of the Board and Scientific Co-Founder of the GI Company, Inc, served as the Chief Academic Officer of Partners HealthCare System and was formerly Mallinckrodt Professor of Medicine and Chief of Gastroenterology at Massachusetts General Hospital and Harvard Medical School.
Mr. Podolsky is a world-renowned researcher who has advanced knowledge of underlying mechanisms of disease and new therapies for gastrointestinal disorders. He is also an international authority on trefoil proteins and innate immunity.
Mr. Podolsky has published and patented widely in his field. He is past editor-in-chief of Gastroenterology, the leading journal in the field, and is immediate Past President of the American Gastroenterological Association.
Mr. Wijers is a Non-Executive Director and Chairman of Heineken NV, Deputy Chairman and Non-Executive Director of Royal Dutch Shell. He is also Chairman of the supervisory board of AFC Ajax and Member of the supervisory board of HAL Holding N.V. ■